Kornimate/medical-research-clean huggingface dataset:
study on the risk of allergy-like reactions after intra-arterial or intra-venous injection of the marketed x-ray contrast medium iopromid

Conditions: Contrast Medium

Summary: iopromide (trade name is ultravist) is on the market for more than 30 years and has been used more than 250 million times as x-ray contrast medium for patients. it is known that iopromide may cause allergy-like reactions after being injected. with this study researchers want to find out, if the risk of severe allergy-like reactions is lower, when iopromide will be injected into an artery, compared to the risk after an injection of iopromid into a vein. to find this out data from four trials on iopromide that are already completed will be combined and newly analyzed. the database used for this analysis will contain data from more than 150,000 patients.


Eligibility criteria:
the study population consists of patients who received a contrast enhanced x-ray examination with iopromide for various clinical reasons. iopromide was administered either intra-venously or intra-arterially.
concentration of trimethylamine oxide (tmao) in blood plasma as a risk factor for vascular cerebral damage

Conditions: Vascular Diseases; Leukoaraiosis; Ischemia, Cerebral

Summary: the primary aim of the current research project is to answer the question, whether plasma trimethylamine n-oxide (tmao) level may be used as a marker of ischemic changes in the brain. tmao is associated with endothelial dysfunction, inflammation and oxidative stress. the hypothesis is that circulating tmao level may predict leukoaraiosis (la) and/or stroke. secondary, the investigators would like to examine whether plasma tmao concentration is related to cognitive impairment and determine whether choline consumption is associated with an incidence of la severity and dementia.

in the study, subjects will be recruited in the hospital among the patients with brain mri performed within past 4 weeks. all mri scans will be reviewed by the neurologist to evaluate ischemic changes. upon detection of la, patients (n=150) will be informed about the study aims. in the same time, aged- and sex-matched control group (n=150) with no detected ischemic changes will be recruited. in each group, the blood samples will be collected, to determine the concentration of plasma tmao, oxidative stress markers, as well as serum endothelial dysfunction markers and biochemical parameters. to determine the cognitive performance psychological test will be carried out. the diet of all recruited participants, with special consideration on the choline-rich products and supplements, will be analyzed.

Eligibility criteria:
inclusion criteria: * the ischemic changes in the brain (diagnosed by neurologist by mri scans) exclusion criteria: * no ischemic changes in the brain (diagnosed by neurologist by mri scans)

Keywords: trimethylamine-n-oxide magnetic resonance imaging cognitive functions
pathology and imaging in kidney allografts

Conditions: Renal Transplant Rejection; Chronic Kidney Diseases; Fibrosis

Summary: this study will perform multi-parametric renal mri in 70 patients with a renal transplant who are undergoing a clinically indicated biopsy of their transplant. the aim of this study is to compare findings on renal mri with those seen on histology.

background: renal transplantation is the optimal treatment for patients with renal failure. however, transplant life-span is finite and commonly limited due to the development of chronic rejection and other causes of irreversible fibrosis. at present, renal transplant biopsy is required to diagnose the cause of transplant dysfunction. renal biopsies are invasive procedures that carry risks of bleeding, damage to the transplant and discomfort to patients. functional magnetic resonance imaging (mri) of the kidneys is an emerging field of research that has potential to non-invasively define and quantify parenchymal renal disease including fibrosis and inflammation. there is a paucity of data correlating multi-parametric renal mri sequences with histological findings on biopsy, especially in patients with renal transplants. study participants: 70 adult renal transplant recipients who have been referred for a clinically indicated biopsy of their transplant kidney. study design: participants will undergo multi-parametric renal mri at time of biopsy. in patients who receive treatment for acute rejection, a second renal mri will be undertaken at completion of treatment. blood tests for fibrosis biomarkers and routine clinical measures of transplant function will be obtained at time of mri scanning. objectives: 1. assess the correlation between functional renal mri sequences and histological markers of fibrosis and inflammation. 2. assess the change in functional mri sequences in response to treatment for acute rejection in renal transplant recipients.

Eligibility criteria:
inclusion criteria: * age \> 18 years * recipient of a kidney transplant * referred for clinically indicated biopsy of transplant kidney * ability to comply with study procedures. * ability to give informed consent. exclusion criteria: * any contraindication to mri * known pregnancy or intent to conceive during the study period * clinical suspicion of delayed graft function as the cause of transplant dysfunction * any other reason considered by a study physician to make the subject inappropriate for inclusion.
a study of a glp-1 analogue in patients with type 2 diabetes treated with metformin.

Conditions: Diabetes Mellitus Type 2

Summary: this 6 arm study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of multiple doses and regimens of a glp-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin. patients will be randomized to receive either subcutaneous placebo, or subcutaneous glp-1 analogue, 5mg, 10mg or 20mg weekly, or 10mg or 20mg every 2 weeks. all patients will continue on their existing metformin treatment regimen throughout the study. the anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-75 years of age; * type 2 diabetes mellitus, with stable metformin treatment for \>=3 months; * stable weight +/-10% for \>=3 months before screening. exclusion criteria: * type 1 diabetes mellitus; * treatment with any anti-hyperglycemic medication other than metformin monotherapy during last 3 months; * use of weight-lowering medications in the last 3 months; * uncontrolled hypertension.
outcomes in pediatric and young adult b-cell malignancies after commercially available immunotherapy

Conditions: Lymphoid Leukemia

Summary: to use a consistent and standardized platform to retrospectively and prospectively study children and young adults with b cell malignancies receiving immunotherapy, blinatumomab and/or inotuzumab ozogamicin.


Eligibility criteria:
inclusion criteria (arm a) \* disease status - b cell precursor acute lymphoblastic leukemia (all) or b cell lymphoma who either: * experienced refractory or relapsed disease, treated with standard chemotherapy, without immunotherapy treatment. or * previously undergone standard of care immunotherapy with fda approved therapies, such as kymriah™ (ctl019, tisagenlecleucel), blinatumomab or * age: greater than or equal to 0 year of age and less than or equal to 26 years of age. inclusion criteria (arm b) * disease status - b cell precursor acute lymphoblastic leukemia (all) or b cell lymphoma * age: greater than or equal to 0 year of age and less than or equal to 26 years of age * patients who are either: * undergoing evaluation for leukapheresis for planned standard of care tisagenlecleucel therapy, or planned for therapy with blinatumomab or inotuzumab. (patients who received prior tisagenlecleucel, blinatumomab or inotuzumab on an established clinical trial and are now scheduled for commercial car, blinatumomab or inotuzumab therapy are also eligible) or * experienced refractory or relapsed b cell precursor acute lymphoblastic leukemia (all) or b cell lymphoma * ability to give informed consent. all subjects ≥ 18 years of age must be able to give informed consent or have legal authorized representative (lar) (i.e. parent or guardian) to consent, if not in capacity to give consent independently. for subjects \ 7 years of age, when appropriate, according to institutional procedures.
psychological factors influencing the patient-reported and functional outcome of acl reconstruction and their sex-specific differences

Conditions: ACL Tear

Summary: psychological parameters among patients undergoing acl reconstruction and their impact on the patient-reported and functional outcome of reconstruction will be prospectively evaluated


Eligibility criteria:
inclusion criteria: * acl tear * over 18 years * patient information and consent * no preexisting knee conditions prior acl tear; exclusion criteria: * under 18 years * preexisting knee conditions * accompanying knee injuries apart from acl tear

Keywords: psychology gender medicine
discover in-hospital cardiac arrest

Conditions: Cardiac Arrest

Summary: the discover in-hospital cardiac arrest (ihca) study is a multicenter, prospective observational study aimed at better understanding variations in practice for the post-in-hospital cardiac arrest patient.

there is considerable debate among experts concerning many components of intra- and post-arrest care. this study aims to increase the evidence base of these components, particularly temperature control, and prognostication in post-in-hospital cardiac arrest patients. in addition to providing insights regarding immediate and long-term post-arrest care, data collected will also be useful in studying variations in cardiopulmonary resuscitation practices. this project is endorsed by the society of critical care medicine's (sccm) discovery, the critical care research network.

Eligibility criteria:
inclusion criteria: * adult (≥18 years old) patients * patients with a cardiac arrest (a lack of palpable pulse or perfusing cardiac activity) while admitted to the hospital * patients admitted to a ward (telemetry or non-telemetry) or an intensive care unit, or are admitted but still in the emergency department waiting for a hospital bed * patients who achieved return of spontaneous circulation (rosc defined as \>20 minutes of sustained spontaneous circulation) or initiated on extracorporeal membrane oxygenation (ecpr) with chest compressions ongoing * patients survived for 6 hours after rosc exclusion criteria: * cardiac arrest in non-inpatients (e.g. outpatients, visitors) * patients whose cardiopulmonary resuscitation (cpr) starts outside of the hospital * non-index arrests (arrests that are not the patient's first arrest during the hospital admission; this also excludes patients who were initially admitted for an out-of-hospital cardiac arrest) * patients suffering ihca in the operating room (or) or post anesthesia care unit (pacu) * patients with cardiac arrest after arriving to an emergency department (ed) but prior to being evaluated and admitted to the hospital * cardiac arrests lasting \<2 minutes (i.e. chest compressions performed \<2 minutes) * cardiac arrests where the patient is transitioned to comfort focused care within 6 hours of return of spontaneous circulation (rosc)

Keywords: in-hospital cardiac arrest post-cardiac arrest
utilization of fixed combination (budesonide/formoterol and salmeterol/fluticasone and beclomethasone/formoterol) in treatment of asthma patients

Conditions: Asthma

Summary: moderate and severe asthma bronchiale is treated by fixed combination (budesonide/formoterol or salmeterol/fluticasone) in the czech republic. there is a hypothesis that doctors should prescribe to each patients per year: six units of fixed combination budesonide/formoterol, or seven units of fixed combination budesonide/formoterol in approach smart, or twelve units of fixed combination salmeterol/fluticasone. with regard to current prices the treatment by fixed combination budesonide/formoterol should cost less. the investigators do not have any data about real life utilization of fixed combination in asthma treatment in czech republic the investigators propose to conduct a non-interventional multicentric retrospective epidemiological study looking into the patients records kept by specialist - allergists and pulmologists. retrospective data for eligible patients will be reviewed by participating investigators, physicians taking care of their patients, and recorded in the electronic crf. only patients who have been treated for asthma bronchiale (classification of severity - moderate or severe persistent asthma) with fixed combination for at least one year could be included into the study. there are no scheduled visits for any patient participating in the study.


Eligibility criteria:
inclusion criteria: * male or female aged 6 years or over * asthma bronchiale, classification of severity - moderate or severe persistent * documented fixed combination (budesonide/formoterol or salmeterol/fluticasone) therapy for at least 18 months

Keywords: asthma bronchiale, fixed combination
dysregulation of the c/ebpa pathway in human lung cancer and search for new biomarkers and/or therapeutic targets

Conditions: Lung Cancer

Summary: the overall goal of this research is to enhance the investigators understanding of the pathways involved in lung cancer, and to identify new biomarkers and/or therapeutic targets. by comparing gene expression between normal lung tissue and tumors growing in lung-specific c/ebpa ko mice, the investigators have identified the bmi-1 proto-oncogene as being abnormally upregulated in c/ebpa-deleted tumors. subsequently, the investigators have validated this observation in human lung cancer, implicating the investigators ko mice are an effective discovery tool for lung cancer research. through similar approaches, the investigators have already identified (sonic hedgehog, shh), and plan to identify other pathways which are abnormally regulated in c/ebpa-/- tumors. in parallel, the investigators will proceed to define the clinical relevance of the shh pathway and the other newly-discovered molecular aberrations, by analyzing their expression and correlate it to c/ebpa expression on the samples of patients with nsclc at nuhs. if the investigators preliminary data on bmi-1 will be confirmed, this proto-oncogene may generate useful correlates that could be used in diagnosis and treatment of lung cancer, as well as identify new prognostic/predictive markers in lung cancer. similarly, shh pathway-components may behave as potential biomarkers and therapeutic tools for c/ebpa-related lung cancers. this proposal seeks to test the hypothesis that pathways which are dysregulated in lung tumors growing in a lung-specific c/ebpa ko model can be utilized as discovery tools to identify genes involved in human lung cancer pathogenesis.


Eligibility criteria:
inclusion criteria: patients with lung cancer
comparative effects of myofascial release and dynamic stretching on flexibility agility, jump and sprint in athletes

Conditions: Athletic Injuries

Summary: the study will be a randomized clinical trial. data was collected from the pakistan sports board. all 44 participants were randomly allotted into 2 groups via lottery method, with 22 participants in each group. 10 participants from cricket and volleyball each, 8 from wrestling, athletes, and football each. participant informed consent was taken priory, and all information was given to them regarding their enrolment in the study. and taken them in confidence that their data was kept confidential and this study does not harm their health. group a participants received the myofascial release technique while group b received the dynamic stretching technique. data were collected pre and post. the session was last for 3 weeks, and each week had 5 sessions. statistical package for the social sciences will be used to analyze the results by using parametric test after confirming normality of data.

myofascial treatment aims to stretch and relax the fascia, allowing musculoskeletal structures to move with relaxation and restore the affected individual functionality. this treatment is frequently known as myofascial release therapy. other people may refer to it as 'myofascial trigger point treatment. a dynamic warm-up, also known as dynamic stretching, involves using a muscle's force generation and the momentum of the body to increase the range of motion of a joint. a dynamic warm-up is frequently included in a specialized warm-up to make the body get ready for the loads that will be put throughout the game. myofascial release and dynamic stretching are different techniques that can be used to flexibility agility, jump and sprint in the early phase which also lead to an increase in athlete's stability, coordination and build confidence in their performances and limit the incidence of injury. the physical ability to move musculoskeletal through their full range of motion is known as flexibility. stretching assists function, and posture, avoid poor body sequence, maintains muscle length, balance, and minimizes the risk of injury the sprint of 40-yard is utilized to evaluate speed, acceleration, and agility. the agility t-test is a famous test for assessing athletes' capacity to run forward, reverse, and lateral. the vertical leap assessment is used to test an athlete's lower limb strength. sit and reach test used for flexibility of athletes.

Eligibility criteria:
inclusion criteria: * age between 15-35 years. * no pain complaint * recreational activity exclusion criteria: * joint, meniscus, or ligament damage * lower extremity surgical history

Keywords: dynamic stretching self-myofascial release
blood biomarker signature in glioma

Conditions: Glioma of Brain

Summary: this is an exploratory, translational and non-interventional clinical study. the aim of this study is to identify a blood biomarker signature for glioma.

the identification of biomarkers (proteins, peptides and micro rnas (mirnas)) in the serum of patients with glioma would be a new, less invasive approach, which could help in the diagnosis of a glioma, and potentially help guide therapeutic decisions. the investigators will investigate the existence of biomarker profiles, which can * distinguish between low and high grade gliomas * correlate with patient outcomes including response to treatment and survival * indicate progression from a low to a high grade glioma. in this study the investigators collect and analyse blood samples taken from patients with suspected newly diagnosed grade ii/iii glioma or glioblastoma multiforme (gbm). blood samples will be collected before any surgical intervention (resection or biopsy) and at various follow-up time points until progression or death. based on the known natural history of gliomas (described above), it is planned to follow patients with grade iii/iv tumours, who receive treatment, for up to 3 years and those with grade ii-iii tumours, (irrespective of treatment) for up to 5 years. ultimately, the investigators envisage the translation of our observations into the hospital setting to aid the distinction between glioma grade ii and grade iii/iv.

Eligibility criteria:
inclusion criteria: 1. all patients with suspected newly diagnosed glioma (grade 2 or 3 or glioblastoma) with planned surgical intervention (resection or biopsy). 2. patient aged 18 years or older 3. patients have to be able to give informed consent exclusion criteria: 1. prior radiotherapy to the central nervous system 2. prior chemotherapy within the last 5 years 3. any prior central nervous system malignancy
defibrotide for the treatment of severe hepatic veno-occlusive disease in hematopoetic stem cell transplant patients

Conditions: Severe Hepatic Veno-Occlusive Disease

Summary: the purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of defibrotide in patients with severe veno-occlusive disease (svod) and (2) evaluate serum and endothelial markers of veno-occlusive disease (vod) through the analysis of blood samples.

this is a historically-controlled, multicenter, open label phase 3 study to determine the safety and efficacy of 25 mg/kg/day of defibrotide (df) for the treatment of severe vod in hematopoietic stem cell transplantation (hsct) patients. in this study, the term "severe vod" is defined as those patients who meet the baltimore diagnostic criteria for vod (total bilirubin \>/= 2.0 mg/dl plus two of the following: ascites, \>/=5% weight gain and hepatomegaly), who also have multi-organ failure (i.e., pulmonary and/or renal dysfunction). this represents a group of patients in whom mortality at day+100 has been estimated to be \>80%. comparisons: the primary parameter is complete response at 100 days following stem cell transplant, utilizing historical controls as a comparator. the historical control database will be generated through a retrospective medical chart review performed at participating centers; the survival outcome of patients who would otherwise have met eligibility criteria for this trial will be compared to the survival observed in patients prospectively treated with defibrotide. secondary parameters include survival rate at 100 days and 6 months post stem cell transplantation (sct), and special studies of endothelial and serum markers for vod. this study will assess safety of the dose and schedule in this setting.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of vod, defined by jaundice (bilirubin \>/= 2 mg/dl) and at least 2 of the following clinical findings, by day+21 post stem cell transplant: ascites; weight gain \>/= 5% above baseline weight; hepatomegaly. * severe vod, defined as vod with multi-organ failure, i.e., presence of one or both of the following, by day+28 post stem cell transplant: renal or pulmonary dysfunction. * provide voluntary written informed consent. exclusion criteria: * pre-existing (prior to sct) cirrhosis * an alternative diagnosis for weight gain, ascites and jaundice * graft-versus-host disease (gvhd) grade b or higher involving liver or gut or grade c or higher involving skin * prior solid organ transplant * dependent on dialysis prior to and/or at the time of sct * dependent on oxygen supplementation prior to sct * significant acute bleeding or hemodynamic instability * requirement for the use of any medications that increase risk of hemorrhage will be excluded from the treatment group

Keywords: defibrotide severe veno occlusive disease multi organ failure stem cell transplant liver regimen related toxicity day 100 survival